Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Image: Scott Olson/Getty Images Novo Nordisk's shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology
Individualised incretin-based treatment for type 2 diabetes
Some chemicals spread throughout the body faster than others and circulate more readily than others
We present hypotheses centered on the mechanisms of GLP-1 RAs, proposing them as potential modulators of aging hallmarks and longevity
In people with type 2 diabetes not using insulin, routine glucose monitoring is of limited additional clinical benefit while adding burden and cost [13, 14]
US$ 23.38
US$ 24.90
US$ 20.00
US$ 29.78
US$ 25.05
